Tag: Recurrence prevention

According to a 2021 guideline update by the Infectious Diseases Society of America (IDSA), fidaxomicin is the preferred treatment for initial and recurrent *Clostridioides difficile* infection (CDI). This shifts the long-standing practice of using vancomycin first-line. The primary reason behind this recommendation is the significant reduction in recurrence rates observed with fidaxomicin compared to vancomycin. So, **why is fidaxomicin preferred over vancomycin?**

Adjuvant therapy has become a cornerstone of modern cancer treatment, representing a proactive strategy to improve long-term patient outcomes. The best reason to administer adjuvant therapy is to eradicate microscopic cancer cells that remain after primary treatment, effectively reducing the risk of cancer recurrence.